<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EC4C05A7-BF3E-406D-9742-E3FF9454B62C"><gtr:id>EC4C05A7-BF3E-406D-9742-E3FF9454B62C</gtr:id><gtr:firstName>Sue</gtr:firstName><gtr:surname>Richards</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U137686856"><gtr:id>CE6009F7-B21D-4BCB-A04D-D8345BFABC3B</gtr:id><gtr:title>Leukaemia Trials (B15)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U137686856</gtr:grantReference><gtr:abstractText>B15. Leukaemia trials and collaborative groups: National and international randomised trials and worldwide collaborative meta-analyses Objectives: To improve the outcome of patients with leukaemia by reliably assessing the relative effects of treatments. Design: Large randomised trials addressing the most important questions in acute lymphoblastic leukaemia (ALL), both in adults and in children, in chronic lymphocytic leukaemia (CLL), and primary thrombocythaemia (PT); and collaborative meta-analyses bringing together the results from all randomised trials worldwide in these leukaemias, and in chronic myeloid leukaemia (CML), myeloma and acute myeloid leukaemia (AML). Techniques: Collaborative groups have been established of those who have done relevant randomised trials to conduct meta-analyses using data on each individual patient. This provides the most reliable information on important treatment questions, allowing examination of effects in different time intervals and subgroups of patients. In the future, these analyses will include newly determined genetic subgroups. The CTSU-run trials also involve collaborations with laboratory scientists, giving additional value to the clinical data. Past and future analyses: Trials completed by the CTSU in the past few years have shown: for adult ALL, the effectiveness of related donor blood or bone marrow stem cell transplants (SCT), and the lack of effectiveness of autologous SCT; for childhood ALL, the benefits of dexamethasone instead of prednisolone, but not of maintenance thioguanine instead of mercaptopurine, and the feasibility of avoiding cranial irradiation; for CLL, the improved rate and maintenance of response with fludarabine plus cyclophosphamide; and for high-risk essential thrombocythaemia, the increased risk of thrombotic and haemorrhagic events when anagrelide instead of hydroxyurea is added to aspirin. Meta-analyses have shown: for myeloma, that interferon treatment gives little, if any, survival benefit; for CML, and standard autologous SCT is not promising as initial treatment; for childhood ALL, radiotherapy can be replaced by long-term intrathecal therapy and high-dose intravenous methotrexate is effective Current and future trials aim to use molecular and genetic methods to better identify those at highest and lowest risk. Questions being addressed include: for childhood ALL, whether treatment can be reduced in very low-risk patients, and outcome in high-risk patients improved by increased intensification with current drugs; for adult ALL, the effects of monoclonal antibodies and reduced intensity transplants; and for early stage CLL, the value of monoclonal antibodies. Future meta-analysis work includes: for childhood ALL, ongoing comparisons of several different treatment elements; in CLL, establishing whether purine analogues or monoclonal antibodies, alone or in combination with other treatments, affect survival; and for adult ALL, assessing how the effects of related donor SCT, or autologous SCT, varies between different groups of patients. Implications for health care: In all types of leukaemia, the collaborative nature of both the trials and the meta-analyses ensures that findings are rapidly implemented into practice, resulting either in health improvements, or in savings in toxicity and cost. For example, childhood ALL is the most common childhood cancer and the substantial improvement in survival over the last 30 years has been achieved by a series of small increments, with randomised trials demonstrating which treatment modifications do (and do not) produce benefit. Although average survival is now around 80%, there remain groups of children with very poor prognosis for whom improved treatment is needed, and others for whom it may be possible to reduce treatment, and hence long term toxicity.</gtr:abstractText><gtr:technicalSummary>B15. Leukaemia trials and collaborative groups: National and international randomised trials and worldwide collaborative meta-analyses Objectives: To improve the outcome of patients with leukaemia by reliably assessing the relative effects of treatments. Design: Large randomised trials addressing the most important questions in acute lymphoblastic leukaemia (ALL), both in adults and in children, in chronic lymphocytic leukaemia (CLL), and primary thrombocythaemia (PT); and collaborative meta-analyses bringing together the results from all randomised trials worldwide in these leukaemias, and in chronic myeloid leukaemia (CML), myeloma and acute myeloid leukaemia (AML). Techniques: Collaborative groups have been established of those who have done relevant randomised trials to conduct meta-analyses using data on each individual patient. This provides the most reliable information on important treatment questions, allowing examination of effects in different time intervals and subgroups of patients. In the future, these analyses will include newly determined genetic subgroups. The CTSU-run trials also involve collaborations with laboratory scientists, giving additional value to the clinical data. Past and future analyses: Trials completed by the CTSU in the past few years have shown: for adult ALL, the effectiveness of related donor blood or bone marrow stem cell transplants (SCT), and the lack of effectiveness of autologous SCT; for childhood ALL, the benefits of dexamethasone instead of prednisolone, but not of maintenance thioguanine instead of mercaptopurine, and the feasibility of avoiding cranial irradiation; for CLL, the improved rate and maintenance of response with fludarabine plus cyclophosphamide; and for high-risk essential thrombocythaemia, the increased risk of thrombotic and haemorrhagic events when anagrelide instead of hydroxyurea is added to aspirin. Meta-analyses have shown: for myeloma, that interferon treatment gives little, if any, survival benefit; for CML, and standard autologous SCT is not promising as initial treatment; for childhood ALL, radiotherapy can be replaced by long-term intrathecal therapy and high-dose intravenous methotrexate is effective Current and future trials aim to use molecular and genetic methods to better identify those at highest and lowest risk. Questions being addressed include: for childhood ALL, whether treatment can be reduced in very low-risk patients, and outcome in high-risk patients improved by increased intensification with current drugs; for adult ALL, the effects of monoclonal antibodies and reduced intensity transplants; and for early stage CLL, the value of monoclonal antibodies. Future meta-analysis work includes: for childhood ALL, ongoing comparisons of several different treatment elements; in CLL, establishing whether purine analogues or monoclonal antibodies, alone or in combination with other treatments, affect survival; and for adult ALL, assessing how the effects of related donor SCT, or autologous SCT, varies between different groups of patients. Implications for health care: In all types of leukaemia, the collaborative nature of both the trials and the meta-analyses ensures that findings are rapidly implemented into practice, resulting either in health improvements, or in savings in toxicity and cost. For example, childhood ALL is the most common childhood cancer and the substantial improvement in survival over the last 30 years has been achieved by a series of small increments, with randomised trials demonstrating which treatment modifications do (and do not) produce benefit. Although average survival is now around 80%, there remain groups of children with very poor prognosis for whom improved treatment is needed, and others for whom it may be possible to reduce treatment, and hence long term toxicity.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>572958</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7832EEFC-F3B9-4FD4-A643-76BF72744A64</gtr:id><gtr:outcomeId>C52BD1965040</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Funding</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>0A2EE6EA-7D08-405E-9546-41261E1D5007</gtr:id><gtr:outcomeId>D34C7E8A4870</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Cochrane Review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DE02E4A9-5B04-41CE-9768-56AB7ABFB554</gtr:id><gtr:impact>Conclusion of review: The results support matched sibling donor allogeneic stem cell transplant as optimal post-remission therapy in ALL patients age greater than or equal to 15.</gtr:impact><gtr:outcomeId>XHC98gcZRLB</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE guideline</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>04AC0B48-6032-4137-AA0F-5C4C95DEDB77</gtr:id><gtr:impact>Fludarabine monotherapy not recommended for first treatment of CLL</gtr:impact><gtr:outcomeId>s8kbRtwZxAC</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3101EB74-F37F-43F7-8A23-B20B6A36778A</gtr:id><gtr:title>The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI.</gtr:title><gtr:parentPublicationTitle>Journal of hematology &amp; oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f68c89256db1a07360471b958535e08"><gtr:id>0f68c89256db1a07360471b958535e08</gtr:id><gtr:otherNames>Halsey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1756-8722</gtr:issn><gtr:outcomeId>pm_15639_29_21996369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>566C281A-5B86-486F-AAAE-1E220B5E9B43</gtr:id><gtr:title>Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/847647222965962de271770b37cf8f6d"><gtr:id>847647222965962de271770b37cf8f6d</gtr:id><gtr:otherNames>Buitenkamp TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_15639_29_22441210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C4B419D-E304-4399-9946-CC5A9828AF77</gtr:id><gtr:title>The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42823a4563d02642fed31691b876daa6"><gtr:id>42823a4563d02642fed31691b876daa6</gtr:id><gtr:otherNames>Mitchell C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>m5ReYsr6TfF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>156903AC-A90F-481C-836F-A8BB9338A77F</gtr:id><gtr:title>Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e91e51ae8da51e169650b724c095747"><gtr:id>5e91e51ae8da51e169650b724c095747</gtr:id><gtr:otherNames>Ensor HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>toHjkPDShFn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C41D4C2-E208-454B-BA17-9785457E310D</gtr:id><gtr:title>Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b14ff350c89ccb4d3870ba42511a1c2c"><gtr:id>b14ff350c89ccb4d3870ba42511a1c2c</gtr:id><gtr:otherNames>Else M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn><gtr:outcomeId>pm_15639_29_22168274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B7B5B88-B76A-4AA1-B4BC-A6B0D3F86154</gtr:id><gtr:title>In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28635fd7d079a4da77aadaaf01ae97d5"><gtr:id>28635fd7d079a4da77aadaaf01ae97d5</gtr:id><gtr:otherNames>Goldstone AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>9132A603B64</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BFCCED-46B1-4B53-8547-EC262D398416</gtr:id><gtr:title>Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b097e1d9592a8e30cdc32f4c090e6b58"><gtr:id>b097e1d9592a8e30cdc32f4c090e6b58</gtr:id><gtr:otherNames>Bosanquet AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>4175947F118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>800616A0-007A-4F7E-8164-F88D43DE787C</gtr:id><gtr:title>Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b14ff350c89ccb4d3870ba42511a1c2c"><gtr:id>b14ff350c89ccb4d3870ba42511a1c2c</gtr:id><gtr:otherNames>Else M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>86AB5218056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CDE4E6E-1660-4F23-AE07-0BA362E05ECC</gtr:id><gtr:title>Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec540d396589c835fdbd03ad39ca12"><gtr:id>6aec540d396589c835fdbd03ad39ca12</gtr:id><gtr:otherNames>Patel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>RH8GhPGQhDS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>576B5325-43D1-482A-99C7-B7A71BC8151D</gtr:id><gtr:title>Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58e6e5e3062155aa6ea6ec31fad815f7"><gtr:id>58e6e5e3062155aa6ea6ec31fad815f7</gtr:id><gtr:otherNames>Ramanujachar R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>076C5A0BCF5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDD27564-01A0-4D8C-BC75-44BA3B2EE01F</gtr:id><gtr:title>Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4de781fcec363ef270f7c97aa412cc5"><gtr:id>f4de781fcec363ef270f7c97aa412cc5</gtr:id><gtr:otherNames>Bond J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>hPc1BPTuW22</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB35287B-F4BE-4B4F-9194-C32E8651D084</gtr:id><gtr:title>Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baa9d67cab5c11a61d8a0aa56d9062fa"><gtr:id>baa9d67cab5c11a61d8a0aa56d9062fa</gtr:id><gtr:otherNames>CLL Trialists' Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_15639_29_22133773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6CE7E92-7E50-49A4-8400-FC88B91690D2</gtr:id><gtr:title>Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a91a7a0e53d2cc009c6c2e42a2be0b6"><gtr:id>1a91a7a0e53d2cc009c6c2e42a2be0b6</gtr:id><gtr:otherNames>Oscier D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>iNmzkmUoAfj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ECB7635-7EBA-48FF-A615-4D8C1EF31A00</gtr:id><gtr:title>Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb4533a2106207fbc24d1e3fb05ed01"><gtr:id>0fb4533a2106207fbc24d1e3fb05ed01</gtr:id><gtr:otherNames>Gonzalez D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>MtWaVQQjTJD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18A98949-B661-4A1F-A41A-D1A5215F574B</gtr:id><gtr:title>Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/439bfad6919ec8fccfc94c3b35ad8b5f"><gtr:id>439bfad6919ec8fccfc94c3b35ad8b5f</gtr:id><gtr:otherNames>Sive JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>pm_15639_29_22409379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A4DDF9B-1AF5-454A-BCDE-A968F4EED29D</gtr:id><gtr:title>Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80c0ed2da7957ef3258d64d0e6a93c5e"><gtr:id>80c0ed2da7957ef3258d64d0e6a93c5e</gtr:id><gtr:otherNames>Michallet M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>oDn8YTJjQrT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1E958CA-DA20-4179-967D-C949911962BF</gtr:id><gtr:title>Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b4a60c16ec58ca7bac3c8cc464a9fba"><gtr:id>6b4a60c16ec58ca7bac3c8cc464a9fba</gtr:id><gtr:otherNames>Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>171DC868100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C80DA414-587A-4756-9F86-6BFA0A74255B</gtr:id><gtr:title>Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42823a4563d02642fed31691b876daa6"><gtr:id>42823a4563d02642fed31691b876daa6</gtr:id><gtr:otherNames>Mitchell C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>cXMTn734zZA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9E40630-0886-4B58-8FF1-A0A412747C25</gtr:id><gtr:title>Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47edbec8c1d53c550fb4063fb8ac857f"><gtr:id>47edbec8c1d53c550fb4063fb8ac857f</gtr:id><gtr:otherNames>Fielding AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>68719D00B0E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF0D5501-5F4D-404A-870E-437540317A73</gtr:id><gtr:title>Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/970ab653ef86b391ac6957dfaaf4ee5e"><gtr:id>970ab653ef86b391ac6957dfaaf4ee5e</gtr:id><gtr:otherNames>Sherborne AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>sosddFb1A7r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9794ED8-441E-49CD-859B-CBBB061EBD60</gtr:id><gtr:title>Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5c4afad9ed63e2ce14e6955cc09639a"><gtr:id>d5c4afad9ed63e2ce14e6955cc09639a</gtr:id><gtr:otherNames>Skowronska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pm_15639_29_23091097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3E914ED-1B52-4A01-B2F9-BCF6BDB5FD8D</gtr:id><gtr:title>HLA-DP?1 Asp84-Lys69 antigen-binding signature predicts event-free survival in childhood B-cell precursor acute lymphoblastic leukaemia: results from the MRC UKALL XI childhood ALL trial.</gtr:title><gtr:parentPublicationTitle>Blood cancer journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14c490a65dfdb359c8adc69864db1f2f"><gtr:id>14c490a65dfdb359c8adc69864db1f2f</gtr:id><gtr:otherNames>Taylor GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2044-5385</gtr:issn><gtr:outcomeId>doi_55faa1aa1fa9a212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C1A074-2514-4F52-8AD2-9D50124BF57A</gtr:id><gtr:title>The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eebb1ceaca6e04c8db574087d54cac78"><gtr:id>eebb1ceaca6e04c8db574087d54cac78</gtr:id><gtr:otherNames>Dearden C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>BB583B7BCF8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13C63B1B-A87C-44B2-BD2E-428029B72B97</gtr:id><gtr:title>Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75fc246188fbc17b5b2dd2408f9e5a41"><gtr:id>75fc246188fbc17b5b2dd2408f9e5a41</gtr:id><gtr:otherNames>Catovsky D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>C768517BBE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FFD190C-C00B-410D-A42D-86CA380E8438</gtr:id><gtr:title>Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ec7269e161400180101c9190342c2d8"><gtr:id>7ec7269e161400180101c9190342c2d8</gtr:id><gtr:otherNames>Wade R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>igHoNEgrW98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE85CC96-E4F6-42AE-972D-17CA313839C8</gtr:id><gtr:title>Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f5854a0f05a4b6cbb8bd46638e73647"><gtr:id>9f5854a0f05a4b6cbb8bd46638e73647</gtr:id><gtr:otherNames>Mansour MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>F5E4DD40A80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8522604F-45C2-4B7C-A298-F104101AC92B</gtr:id><gtr:title>David Galton--reminiscences.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a00cf5073cfab5fca7f7dbf9c89219a"><gtr:id>9a00cf5073cfab5fca7f7dbf9c89219a</gtr:id><gtr:otherNames>Peto R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn><gtr:outcomeId>B40EC7D8FE2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D9FE8F0-3802-4068-8396-12B4A532CF72</gtr:id><gtr:title>No association of HLA-A supertype with outcome in childhood acute lymphoblastic leukaemia: results of the UKALL XI trial.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a091fe1e84d9276640f84e103081b6d"><gtr:id>3a091fe1e84d9276640f84e103081b6d</gtr:id><gtr:otherNames>Thompson PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>JauaT4vkwfo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86ABDC44-E5B5-4578-9AED-082F9F6469D1</gtr:id><gtr:title>Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7955f01db180d60d0a9a20c1ce54822e"><gtr:id>7955f01db180d60d0a9a20c1ce54822e</gtr:id><gtr:otherNames>Campbell PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>oE2acyFaeWw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27D20ACF-EBB8-44E5-85F8-12389E311B2E</gtr:id><gtr:title>The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9852b797980118fe42300dbc7ccbba64"><gtr:id>9852b797980118fe42300dbc7ccbba64</gtr:id><gtr:otherNames>Matutes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_15639_29_22810506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>404D9741-DBBC-4D3F-A38F-8B420F5C8C5A</gtr:id><gtr:title>Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/463933391c12eae570d0e95722351f29"><gtr:id>463933391c12eae570d0e95722351f29</gtr:id><gtr:otherNames>Qureshi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>E7SZJcypgeo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>289F7C86-2B77-44A7-A5C9-C9267390F92E</gtr:id><gtr:title>Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/addeac2b090e0b2e5401812309c20a51"><gtr:id>addeac2b090e0b2e5401812309c20a51</gtr:id><gtr:otherNames>Eden T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>p1drhKDHwti</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A68EB6BA-4833-4870-BEA4-65CC57C7FFBE</gtr:id><gtr:title>Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c3dfc29a6a9bfdfe9b9fd4545b50992"><gtr:id>8c3dfc29a6a9bfdfe9b9fd4545b50992</gtr:id><gtr:otherNames>Rai L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>fqgxCHFNmwm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BDE0705-5C8A-4707-8D91-4B8BF3CBB690</gtr:id><gtr:title>The immunostimulatory activity of 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxythiazole [3,2-alpha]-benzimidazole-2-acetic acid (NSC 208828).</gtr:title><gtr:parentPublicationTitle>European journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a4b753969cb84b0158552e3e54127ca"><gtr:id>7a4b753969cb84b0158552e3e54127ca</gtr:id><gtr:otherNames>Tagliabue A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1978-01-01</gtr:date><gtr:issn>0014-2964</gtr:issn><gtr:outcomeId>U16rQ9FpnAp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D95ED058-F997-407A-8F95-871223DC2141</gtr:id><gtr:title>Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4395c1f517f39a43e994c2a99d11628"><gtr:id>b4395c1f517f39a43e994c2a99d11628</gtr:id><gtr:otherNames>Lin K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15639_29_22675167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7392C4E8-1271-40C3-9DD3-9EB04BBC8577</gtr:id><gtr:title>Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7406bbd577b33015e61a3d2b6c2257b0"><gtr:id>7406bbd577b33015e61a3d2b6c2257b0</gtr:id><gtr:otherNames>Konn ZJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>nRA7XDtbF6a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E2B7D51-89C2-4902-90DE-1C438564F5D5</gtr:id><gtr:title>Outcomes after induction failure in childhood acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dc782b299f823e21ef92068c9ca5cf7"><gtr:id>9dc782b299f823e21ef92068c9ca5cf7</gtr:id><gtr:otherNames>Schrappe M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15639_29_22494120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9F24ED0-5BC9-40C7-B016-DA4058C6305F</gtr:id><gtr:title>Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-analysis of six randomized trials.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94338b51d65639bca70ecec1d0f9cca8"><gtr:id>94338b51d65639bca70ecec1d0f9cca8</gtr:id><gtr:otherNames>CML Autograft Trials Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>AF2929C88A1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A59D162-232B-456E-94F3-B67D8EAE1785</gtr:id><gtr:title>Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14c490a65dfdb359c8adc69864db1f2f"><gtr:id>14c490a65dfdb359c8adc69864db1f2f</gtr:id><gtr:otherNames>Taylor GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>E39B433EC21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C72BD11F-9ABB-4A11-AF9C-61349B67C895</gtr:id><gtr:title>Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47edbec8c1d53c550fb4063fb8ac857f"><gtr:id>47edbec8c1d53c550fb4063fb8ac857f</gtr:id><gtr:otherNames>Fielding AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>89EE63C4B77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EAA626B-3D3B-470C-939F-E913D57D1E2C</gtr:id><gtr:title>Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ab45e2374bc8925368055e8466bd49d"><gtr:id>6ab45e2374bc8925368055e8466bd49d</gtr:id><gtr:otherNames>Escherich G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>JRPgF1F6hxs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE86A4E0-1922-4B47-9C9D-547C8253AC89</gtr:id><gtr:title>Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4306522c4553baffbe88b7dbfef99965"><gtr:id>4306522c4553baffbe88b7dbfef99965</gtr:id><gtr:otherNames>Moorman AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>B58562FE404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4B7F6BB-D1C3-4F91-8FF3-6BD95381B072</gtr:id><gtr:title>Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fcd0ce844defe78f584dbdd62079d9d"><gtr:id>2fcd0ce844defe78f584dbdd62079d9d</gtr:id><gtr:otherNames>Richards S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>pm_15639_29_22693038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98D00DC1-FAB6-42E6-9A18-7B3FACA50B86</gtr:id><gtr:title>Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4306522c4553baffbe88b7dbfef99965"><gtr:id>4306522c4553baffbe88b7dbfef99965</gtr:id><gtr:otherNames>Moorman AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>MFh5xEkVnzF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4E1F085-9C29-418D-B065-AB7EED3AABFE</gtr:id><gtr:title>WT1 mutations in T-ALL.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c050ebd0939bd2b0d742c7262e3ec1a0"><gtr:id>c050ebd0939bd2b0d742c7262e3ec1a0</gtr:id><gtr:otherNames>Tosello V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>C45DBD50262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC541130-B969-4933-BBE3-208D36EA907F</gtr:id><gtr:title>Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dd64a3dfe5a823e7fb4acb181251030"><gtr:id>4dd64a3dfe5a823e7fb4acb181251030</gtr:id><gtr:otherNames>Krishnan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>St2Rz1wTUKs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>590B2E96-6339-418E-9474-45205E637194</gtr:id><gtr:title>Evidence for under-diagnosis of childhood acute lymphoblastic leukaemia in poorer communities within Great Britain.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8985b172e326f4c4ba0a0ff0a3f9f1ad"><gtr:id>8985b172e326f4c4ba0a0ff0a3f9f1ad</gtr:id><gtr:otherNames>Kroll ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_15639_29_22472883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B43CEE9-FD2A-42E9-BF37-1CA08AE63D97</gtr:id><gtr:title>High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec540d396589c835fdbd03ad39ca12"><gtr:id>6aec540d396589c835fdbd03ad39ca12</gtr:id><gtr:otherNames>Patel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>4952CCB3881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BAE6F45-0237-427A-AC46-70A11282CBA3</gtr:id><gtr:title>Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd8512582a2495e8042a388a114ad30"><gtr:id>acd8512582a2495e8042a388a114ad30</gtr:id><gtr:otherNames>Jenkinson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>pm_15639_29_22814294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>269FD83A-3F25-4136-872F-E7014C8D8034</gtr:id><gtr:title>Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e49742b040c5a0b64ded49290b7484"><gtr:id>01e49742b040c5a0b64ded49290b7484</gtr:id><gtr:otherNames>Sellick GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>792DDBF610E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08D85573-3791-4052-B4C6-EEFF1ADF8E1B</gtr:id><gtr:title>T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f678584bd9434ddbe82dfdfa39e71a"><gtr:id>34f678584bd9434ddbe82dfdfa39e71a</gtr:id><gtr:otherNames>Marks DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>BVDKUSq1QWa</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U137686856</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>